Synthetic Blood Announces Department Of Defense Grant For Traumatic Brain Injury Clinical Trial With Oxycyte
"With this grant, we will be able to double our planned enrollment in the Phase IIb trial to 200 TBI patients, providing a larger statistical basis for evaluating Oxycyte's effectiveness as a treatment in this indication," stated Dr Bullock, who was a principal investigator in Synthetic Blood's Phase IIa pilot study in TBI and currently serves as Co-Chairman of the Company's Scientific Advisory Board. "We are scheduled to commence the double-blind, placebo-controlled Phase IIb trial in April of this year."
"If results from the Phase IIb clinical trial in this larger patient population are similar to those of our small Phase IIa pilot study, and with the support of the DoD, we may be able to accelerate Oxycyte's market approval," stated Robert Larsen, Interim President and CEO of Synthetic Blood. "If successful, this study should have a significant impact on arresting the advancement of brain damage in these patients and result in a one-shot emergency room treatment that could be used for all brain-injured patients."
Positive data from the Oxycyte pilot study in TBI patients demonstrated that Oxycyte was more effective in increasing brain oxygen tension levels and impacting other brain chemistries that contribute to favorable clinical outcomes in TBI patients than breathing either 100 percent or 50 percent oxygen.
About 12,000 coalition troops have been injured in the global war on terror, and severe TBI has been termed "the signature injury" in this conflict, noting that TBI is often accompanied by multiple additional injuries as a result of improvised explosive devices (IEDs) or shrapnel. Importantly, TBI is the largest cause of death and severe disability among persons under the age of 40 in the U.S., as well as worldwide. Most TBI victims die or remain severely disabled due to inadequate early cerebral oxygenation or perfusion, which are always present around focal injuries.
About Synthetic Blood International
Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development an oxygen therapeutic/blood substitute and a liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes.
Safe-Harbor Statement The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward looking information made on the Company's behalf. All statements other than statements of historical facts which address the Company's expectations of source of capital or which express the Company's expectations for the future with respect to financial performance or operating strategies, can be identified as forward-looking statements. Such statements made by the Company are based on knowledge of the environment in which it operates, but because of the factors previously listed, as well as other factors beyond the control of the Company, actual results may differ materially from the expectations expressed in the forward-looking statements.
Synthetic Blood International
Sintetice de sânge anunta de Departamentul Apararii acorda pentru creier Leziuni traumatice studiu clinic cu Oxycyte - Synthetic Blood Announces Department Of Defense Grant For Traumatic Brain Injury Clinical Trial With Oxycyte - articole medicale engleza - startsanatate